Minimum Bactericidal Concentration (MBC) Testing

Advanced Minimum Bactericidal Concentration (MBC) Testing Services – From Standard MBC Determination to Mechanistic Time‑Kill Kinetics and Combination Synergy Assessment

The determination of the minimum bactericidal concentration (MBC) is a critical extension of antimicrobial susceptibility testing, providing the most direct quantitative measure of the bactericidal (killing) activity of an antimicrobial agent. While the minimum inhibitory concentration (MIC) indicates the concentration that inhibits visible growth, the MBC defines the concentration that actively kills a defined proportion (typically ≥ 99.9%) of the initial microbial population. This distinction is essential for the clinical management of life‑threatening infections (e.g., endocarditis, meningitis, sepsis), for the evaluation of novel bactericidal agents, and for the optimisation of combination therapies. Regulatory and clinical standards, including CLSI M26 (Methods for Determining Bactericidal Activity of Antimicrobial Agents) and ISO 20776‑1, require that MBC determinations be performed using validated, reference‑quality procedures with strict quality control and clear endpoint interpretation. However, a reliable MBC assay is technically demanding; it depends on the accurate determination of the MIC, the precise sub‑culturing of the MIC wells, the selection of the appropriate inoculum and incubation conditions, and the rigorous enumeration of surviving colonies. A poorly performed test can lead to misclassification of an agent as bacteriostatic or bactericidal, overestimation of killing, or failure to detect tolerance. Our ISO/IEC 17025‑accredited and GMP‑compliant laboratory offers a fully integrated MBC testing platform, encompassing the gold‑standard broth microdilution method for MBC determination, alongside advanced time‑kill kinetic studies, synergy testing, and mechanistic characterisation of bactericidal activity. We deliver quantitative, traceable MBC values, kill‑curve profiles, and, where required, a detailed analysis of the rate and extent of killing, as well as the potential for tolerance or persistence. Our expert microbiologists provide comprehensive interpretation, enabling you to make informed clinical decisions, validate new antimicrobial candidates, and meet the most stringent regulatory and quality requirements.

1. The Scientific and Clinical Rationale for Accurate MBC Determination

The MBC is a fundamental pharmacodynamic parameter that defines the intrinsic killing potential of an antimicrobial. It is used for multiple critical purposes: (a) to guide the selection of bactericidal versus bacteriostatic therapy for infections where host immune response is compromised or where the infection site is difficult to penetrate; (b) to evaluate the activity of new antibacterial agents and to determine whether they are bactericidal or bacteriostatic; (c) to assess the potential for antibiotic tolerance (a phenomenon where the organism is inhibited but not killed, often associated with treatment failure); (d) to support the development of combination therapies by determining the fractional bactericidal concentration (FBC) index; and (e) to provide pharmacodynamic data for the design of optimal dosing regimens. The MBC is determined by sub‑culturing the wells from the MIC plate that show no visible growth onto antibiotic‑free agar and counting the number of surviving colonies. The MBC is defined as the lowest concentration that reduces the initial inoculum by ≥ 99.9% (equivalent to a 3‑log reduction). The choice of the method – whether broth microdilution with sub‑culture (the reference method), agar dilution, or the gradient strip modification – must be justified based on the organism, the antimicrobial, and the required precision. All methods must be validated to demonstrate that they are accurate, reproducible, and free from carry‑over effects. Our service begins with a thorough consultation to define the optimal MBC strategy, ensuring that the data are scientifically robust and compliant with the relevant CLSI and ISO standards.

2. Our Comprehensive MBC Testing Platform – Reference and Advanced Methods

We maintain a complete suite of validated MBC methods, all performed in a dedicated microbiology facility with stringent quality controls, and using certified reference strains (e.g., E. coli ATCC 25922, S. aureus ATCC 29213, P. aeruginosa ATCC 27853) for daily quality assurance. Our portfolio includes:

2.1 Reference Broth Microdilution MBC Determination (CLSI M26)
We perform the MBC as an extension of the reference broth microdilution (BMD) method. After determining the MIC in 96‑well microtiter plates (using cation‑adjusted Mueller‑Hinton broth), we transfer an aliquot (typically 10‑100 µL) from each well that shows no visible growth (including the MIC well and the higher concentrations) onto antibiotic‑free Mueller‑Hinton agar plates. We quantify the surviving colonies after 24‑48 hours of incubation. The MBC is defined as the lowest antimicrobial concentration that reduces the initial inoculum by ≥ 99.9%. We include all appropriate controls – the growth control, the Sterility control, and the positive QC strain controls. We report the MBC value in μg/mL and the MBC/MIC ratio (to classify the agent as bactericidal, if MBC ≤ 4× MIC, or as bacteriostatic, if MBC > 4× MIC).

2.2 Agar Dilution MBC – For Fastidious Organisms and Anaerobes
For organisms that are difficult to grow in broth, we use the agar dilution method for MBC determination. The antimicrobial is incorporated into Mueller‑Hinton agar (supplemented as required), and the organism is spot‑inoculated at a defined inoculum. After incubation, the plates are inspected for growth, and the concentration that yields no visible growth is taken as the MIC. To determine the MBC, the surface of the agar at the MIC and higher concentrations is swabbed and sub‑cultured onto fresh agar plates to enumerate survivors. We define the MBC as the lowest concentration that yields no colonies (or < 0.1% survival).

2.3 Gradient Strip (E‑test) Modification – For Rapid MBC Estimation
We use a validated modification of the gradient strip (E‑test) method for a rapid estimation of the MBC. After determining the MIC with the gradient strip on agar, we cut out the agar cylinder at the MIC zone and sub‑culture it in broth to determine the presence of viable cells. While this method is less precise than the reference BMD method, it is useful for screening and for organisms with limited growth conditions. We only offer this as a screening service, with reference BMD confirmation for critical samples.

2.4 MBC for Fungi – Minimum Fungicidal Concentration (MFC)
We determine the minimum fungicidal concentration (MFC) for yeasts and moulds using a similar principle. After determining the MIC by broth microdilution (in RPMI‑1640), we sub‑culture the wells from the MIC plate onto Sabouraud dextrose agar and incubate for an appropriate time. The MFC is defined as the lowest concentration that reduces the initial inoculum by ≥ 99.9% (or that yields no growth on sub‑culture). We follow the CLSI M27 and M38 guidelines for the interpretation of fungicidal activity.

2.5 Time‑Kill Kinetics – The Gold Standard for Characterising the Rate of Killing
Beyond the endpoint MBC, we perform time‑kill kinetic studies to characterise the rate and time‑course of bactericidal activity. We expose the organism to multiple concentrations of the antimicrobial (e.g., 0.5×, 1×, 2×, 4×, 8× MIC) and take samples at defined time points (0, 1, 2, 4, 6, 12, and 24 hours). We plate the samples onto agar and count the surviving colonies. From this, we construct kill‑curves and calculate the regrowth time, the rate of killing (e.g., the log10 reduction per hour), and the post‑antibiotic effect (PAE). This method is essential for evaluating the pharmacodynamic profile of new agents and for comparing the activity of different compounds.

2.6 Synergy and Additivity Studies – Checkerboard and Time‑Kill Combination Assays
We use the checkerboard method to determine the fractional bactericidal concentration (FBC) index for combinations of two or more agents. After determining the MBC of each agent alone, we perform a two‑dimensional dilution of the combinations and determine the MBC for the combination. We calculate the FBC index (ΣFBC = MBCₐ in combination/MBCₐ alone + MBC_b in combination/MBC_b alone) to classify the interaction as synergistic (FBC ≤ 0.5), additive (FBC 0.5‑1), or antagonistic (FBC > 4). We also complement this with time‑kill kinetic studies for the combination at the FBC concentrations.

2.7 Tolerance and Persister Detection – Distinguishing Non‑Killing from True Resistance
We assess the tolerance of an organism (where the MIC is low but the MBC is high, leading to a high MBC/MIC ratio) using the MBC/MIC ratio (values > 32 indicate tolerance). We also detect the presence of persister cells by performing time‑kill kinetics with a high initial inoculum (10⁷‑10⁸ CFU/mL) and observing a biphasic killing curve, indicating the presence of a small subpopulation that survives despite high concentrations. This is critical for understanding treatment failure and the risk of relapse.

3. Advanced Capabilities – Mechanistic Deep‑Dive, Custom Panels, and Regulatory Support

For clients requiring a deeper understanding of the bactericidal mechanism or a high‑level validation of their antimicrobial candidate, we offer a suite of customised, research‑grade services that go beyond routine MBC determination:

3.1 Mechanistic Bactericidal Profiling – Morphological and Molecular Analysis
We combine MBC and time‑kill data with flow cytometry (using viability dyes) and transmission electron microscopy (TEM) to assess the mode of killing (e.g., cell lysis, membrane disruption, or metabolic shutdown). We also perform whole‑genome sequencing (WGS) to identify any mutations that may lead to tolerance or persistence.

3.2 Mutant Prevention Concentration (MPC) and Resistance Frequency
We determine the mutant prevention concentration – the concentration required to prevent the growth of the first‑step resistant mutants – using the same high‑inoculum method (10¹⁰ CFU/mL) and measuring the frequency of spontaneous resistance (the number of mutants per 10¹⁰ cells). This is essential for assessing the potential for resistance development during therapy.

3.3 Biofilm Bactericidal Assays – MBEC and Biofilm Time‑Kill
For infections associated with biofilms, we perform minimum biofilm eradication concentration (MBEC) assays and biofilm time‑kill kinetics, using a standardised Calgary biofilm device or a flow‑cell system. We assess the killing of biofilm‑embedded cells, which may show a significantly higher MBC compared to planktonic cells.

3.4 Pharmacodynamic (PD) Modelling – In‑Vitro PK/PD Correlation
We use the time‑kill kinetic data to construct pharmacodynamic models (e.g., the Hill equation) that describe the relationship between the antimicrobial concentration and the killing rate. We can simulate the effect of different dosing regimens and provide data for the design of in‑vivo efficacy studies.

3.5 Method Validation and Regulatory Submission Support
We provide full method validation for your MBC assay, including: (a) accuracy (against the reference BMD method); (b) precision (intra‑assay, inter‑assay, and inter‑operator); (c) reproducibility (across multiple media and instrument settings); (d) robustness to variations in inoculum, incubation time, and sub‑culture volume; and (e) the limit of detection for surviving cells. The validation report is structured to meet the requirements of the FDA, EMA, and other agencies.

4. Data Integrity, Standardisation, and Comprehensive Reporting

All assays are conducted under a strict quality management system that includes the use of certified reference strains, routine daily controls, and participation in proficiency testing schemes (e.g., UK NEQAS). Our reports provide:

• Full method description – detailing the organism, the antimicrobial, the test method, the inoculum, the media, and the incubation conditions.
• Detailed results – including the MIC, the MBC (in μg/mL), the MBC/MIC ratio, and the classification (bactericidal if MBC ≤ 4× MIC, bacteriostatic if MBC > 4× MIC).
• Time‑kill kinetic data – including the kill curves (log10 CFU/mL versus time) and, if requested, the rate of killing, the regrowth time, and the PAE.
• Quality control data – the results of the concurrent QC strains, confirming the validity of the test run.
• Graphical outputs – including kill‑curves, synergy isobolograms, and FBC index calculations.
• Interpretative comments – on the clinical significance of the bactericidal activity, the potential for tolerance, and any recommendations for further testing (e.g., combination studies, biofilm assays).

Our reports are authored by senior clinical microbiologists and pharmacologists who provide not just raw data, but contextual insights to guide your clinical, research, or regulatory decisions.

Turnaround times: 5‑7 working days for standard MBC determination, 7‑10 working days for time‑kill kinetics, and 2‑3 weeks for combination synergy and mechanistic studies. Express services are available for urgent projects.

5. Our Unmatched Expertise – Why Choose Our Laboratory for MBC Testing

We are one of the few laboratories that hold ISO/IEC 17025 accreditation and GMP compliance for the full spectrum of MBC methods, including BMD‑based MBC, time‑kill kinetics, synergy testing, and biofilm assays. Our integrated infrastructure combines a reference microbiology laboratory, a state‑of‑the‑art flow cytometry facility, and a bioinformatics core – enabling cross‑verification of results and a comprehensive understanding of the bactericidal phenotype and the underlying mechanisms. Our team comprises PhD‑level clinical microbiologists, pharmacologists, and bioinformaticians with extensive experience in MBC method development, validation, and regulatory submissions, and we have a proven track record of supporting antimicrobial development, clinical decision‑making, and public health surveillance.

We offer unparalleled flexibility: we accept a wide range of clinical and environmental isolates – from common pathogens (E. coli, S. aureus, Klebsiella, Pseudomonas) to fastidious organisms (Streptococcus, Haemophilus, anaerobes, and mycobacteria) – and we provide customised antimicrobial panels for novel agents and combination regimens. Our secure online portal enables real‑time tracking, access to raw data, and downloadable certificates of analysis.

Our modular pricing ensures cost‑effectiveness: you select the level of analysis – from a simple MBC determination to a full time‑kill plus synergy and resistance‑frequency study – with discounts for routine monitoring programmes and bulk submissions. We also provide training, method transfer, and technical consultancy to help you build or strengthen your internal MBC testing capabilities.

With a proven history of serving over 80 clients in the pharmaceutical, clinical, and biotechnology sectors, we have enabled our partners to characterise the killing activity of antimicrobials, optimise combination therapies, and accelerate drug development. We invite you to leverage our expertise for your minimum bactericidal concentration testing needs.

Contact our technical experts today to discuss your test organisms, antimicrobial panels, and specific requirements. We will design a tailored testing plan and provide a detailed proposal within one business day.